COVID-19 concerns may undermine vaccine rates for seasonal flu

September 28, 2020 -- COVID-19 concerns may undermine vaccine rates for seasonal flu

Web version

September 28, 2020

Top Stories

COVID-19 concerns may undermine vaccine rates for seasonal flu

Only a third of parents believe that the flu vaccine will be more important this year, and 1 in 7 parents will not vaccinate their child due to concerns about COVID-19, according to the results of a new poll. The poll results underscore concerns that there could be a double impact of seasonal flu and COVID-19 this winter.

Passive vaccines with mAbs may be effective for COVID-19

Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially useful as therapeutic and prophylactic agents for passive vaccination, assuming their administration does not trigger unwanted side effects. The findings of the new study were published in Cell on September 26.

Is 'bespoke' therapy the future of genomic medicine?

Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals suffering from genetic diseases, as discussed in a session of the second annual American Society for Gene & Cell Therapy (ASGCT) Policy Summit on September 24.

Bioprocessing

Amarna Therapeutics, FPS examine gene therapy platform

Amarna Therapeutics will collaborate with scientists from Progreso y Salud Foundation (FPS) of Spain to jointly examine the efficacy of Amarna's Svec gene delivery vector to develop effective immunotherapies for type 1 diabetes and multiple sclerosis.

Javelin, Pfizer to develop organ-on-a-chip platform

Javelin Biotech has entered a three-year collaboration with Pfizer to design and build a platform to evaluate absorption, distribution, metabolism, and excretion properties of small molecules on an organ-on-a-chip platform.

Cancer & Disease Research
Sponsored by Beckman Coulter

ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine

ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.

Endo to provide fill-finish services for Novavax COVID-19 vaccine

Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's COVID-19 vaccine candidate.

Neurophth's gene therapy granted orphan drug designation

Neurophth Therapeutics' lead candidate, NR082, an adeno-associated virus-based gene therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Leber hereditary optic neuropathy associated with an ND4 mutation.

Ideaya, Pfizer expand clinical collaboration

Ideaya Biosciences has expanded its clinical trial collaboration and supply agreement with Pfizer for the combination study of IDE196, protein kinase C inhibitor, and crizotinib, a c-MET inhibitor.

Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy

Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.

Genomics
Sponsored by Nvidia

Is 'bespoke' therapy the future of genomic medicine?

Science serves society, a crucial concept for gene therapy governance

With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed how far science has advanced in a short period of time, and how the scientific community is rising to the challenge of gaining public buy-in for gene therapy.

Riffyn, Imperial College partner to speed up synthetic biology research

Riffyn and Imperial College in London have formed a partnership aimed at bringing Riffin's Nexus process data system to the public synthetic biology research community in the U.K.

Immunology
Sponsored by Beckman Coulter

COVID-19 concerns may undermine vaccine rates for seasonal flu

Clover touts positive preclinical results for COVID-19 vaccine

Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GlaxoSmithKline or Dynavax.

Are people in your state getting vaccinated?

Support for a COVID-19 vaccine continues to wane even as companies report being closer to bringing one to the public. This may not be surprising, considering people in many U.S. states don't get inoculated for other diseases such as polio and the flu.

Leap granted Fast Track designation for mAb to treat gastric cancers

Leap Therapeutics said that its DKN-01 monoclonal antibody (mAb) has received Fast Track designation by the U.S. Food and Drug Administration for treatment of gastric and gastroesophageal junction adenocarcinomas.

Proteomics

Passive vaccines with mAbs may be effective for COVID-19

What Your Colleagues are Buzzing About

Gateway receptor for SARS-CoV-2 helps explain variability of COVID-19

Analysis of COVID-19 literature identifies possible knowledge gaps

•		Do not reply to this e-mail as it was sent automatically from an unmonitored account.

•		Unsubscribe from the Letter from the Editor.

•		Reset your password.

•		Contact scienceboard.net support.

•		scienceboard.net Privacy Policy.

•		Email sent to: .

If you like this content, please share it with a colleague!

Join Us

COVID-19 concerns may undermine vaccine rates for seasonal flu

Learn about ScienceBoard